A team of Scientists which includes researchers in the UK Centre for Mammalian Synthetic Biology, have taken a key step towards improving an emerging class of treatments for Parkinson’s disease. The advance could markedly improve a next generation of therapies for the condition, which affects around one in 350 people in the UK, by aiding in the development of the promising treatment – known as cell replacement therapy – which was first used in a clinical trial this year. The study, published in the European Journal of Neuroscience, was funded by the UK Centre for Mammalian Synthetic Biology, the pharmaceutical company UCB Biopharma and The Cure Parkinson’s Trust.
